Drug Search Results
More Filters [+]

KER-012

Alternative Names: ker-012, ker012, ker 012, RKER-012, RKER012, RKER 012
Latest Update: 2024-01-29
Latest Update Note: News Article

Product Description

KER-012 is designed to bind to and inhibit the signaling of TGF-ß ligands, including activin A and activin B, which are key regulators of bone remodeling that act to suppress bone growth. (Sourced from: https://ir.kerostx.com/news-releases/news-release-details/keros-therapeutics-presents-results-preclinical-study-ker-012)

Mechanisms of Action: Activin A Inhibitor,Activin B Inhibitor

Novel Mechanism: Yes

Modality: Peptide/Protein

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Keros Therapeutics
Company Location: LEXINGTON MA 02421
Company CEO: Jasbir Seehra
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for KER-012

Countries in Clinic: Australia, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 2: Familial Primary Pulmonary Hypertension|Heart Failure, Chronic|Hypertension, Pulmonary

Phase 1: Hypertension|Osteoporosis, Postmenopausal

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TROPOS Study

P2

Recruiting

Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension

2025-06-30

ACTRN12623001290684

P2

Not yet recruiting

Heart Failure, Chronic

2024-06-14

ACTRN12621001077853

P1

Active, not recruiting

Osteoporosis, Postmenopausal|Hypertension

2022-03-10

Recent News Events